MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers

Chemo-resistance is an important barrier to effective treatment of ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors are currently promising targeted drugs used to treat BRCA-mutant ovarian cancer. Ovarian cancer patients with BRCA 1/2 mutations appear to benefit better from PARP inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yue, Wu, Jing, Dong, Xiaoying, Zhang, Jingzi, Meng, Chao, Liu, Guoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770486/
https://www.ncbi.nlm.nih.gov/pubmed/33360300
http://dx.doi.org/10.1016/j.tranon.2020.100987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770486/
https://www.ncbi.nlm.nih.gov/pubmed/33360300
http://dx.doi.org/10.1016/j.tranon.2020.100987

Ejemplares similares